STAT+: The view from overseas on tumult in U.S. science
And other biotech news stories from the day.
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Happy V-Day! Gorge on heart-shaped chocolate and ponder the implications of RFK Jr. being sworn in as health secretary. Today, we talk about that, as well as new cancer data from Corbus Pharma, Europe’s reaction to talk of an academic brain drain in the U.S., and more.
The need-to-know this morning
- Moderna missed earnings forecasts, posting a net loss of $1.1 billion, or $2.91 per share, 23% below the expectations of analysts polled by Visible Alpha. Revenue was 4% higher than forecasts, mostly due to higher than expected sales of Moderna’s Covid vaccine, SpikeVax. In January, the company cut its sales guidance for 2025 by $1 billion to $1.5 billion to $2.5 billion. Analysts still generally expect it to hit the higher end of that range.
RFK Jr. sworn in as health secretary, leading MAHA
Robert F. Kennedy Jr. has been sworn in as the U.S. health secretary, and was immediately appointed chair of President Trump’s new “Make America Healthy Again” commission. The aim is investigating a rise in childhood chronic illnesses, and delivering policy recommendations. The commission will examine factors like diet, environmental toxins, medical treatments, and corporate influence, with an initial report due in 100 days.
